Journal of Medical Virology最新文献

{"title":"Development and Characterization of an Inducible Bacterial Artificial Chromosome System for Studying Lytic Replication and Pathogenesis of Kaposi's Sarcoma-Associated Herpesvirus","authors":"Xue Xu,&nbsp;Peixian Dong,&nbsp;Wenwei Li,&nbsp;Xiaoqian Wang,&nbsp;Zizhen Ming,&nbsp;Zhenshan Liu,&nbsp;Fanxiu Zhu,&nbsp;Qiming Liang","doi":"10.1002/jmv.70392","DOIUrl":"https://doi.org/10.1002/jmv.70392","url":null,"abstract":"<div>\u0000 \u0000 <p>Bacterial artificial chromosome (BAC) is widely used to manipulate herpesvirus genome and generate recombinant virus. Here, we developed a new KSHV BACmid, namely as iBAC, by replacing the EGFP with TET3G transactivator under EF1α promoter and inserted Tet response elements in the promoter of RTA in the original KSHV BAC16 clone and characterized KSHV lytic replication in SLK-iBAC cells. SLK-iBAC cells developed more efficient lytic replication and generated more progeny virus than iSLK-BAC16 cells upon the same conditions of doxycycline treatment. Since SLK-iBAC cells only occupied hygromycin selection marker, it is convenient to generate cellular gene knockout via lentivirus-mediated CRISPR-Cas9 or stably express viral or cellular gene via lentivirus followed by antibiotic selection, making iBAC system a better tool to identify cellular targets of viral proteins in the context of virus infection or study the role of viral or cellular genes for KSHV lytic replication and pathogenesis. In addition, iBAC is color-free and can be utilized to track subcellular localization of viral proteins or colocalization between different viral proteins by introducing fusing fluorescent proteins into the BAC backbone. Therefore, the new KSHV iBAC is a powerful inducible tool to study KSHV lytic replication and pathogenesis in cell model.</p></div>","PeriodicalId":16354,"journal":{"name":"Journal of Medical Virology","volume":"97 5","pages":""},"PeriodicalIF":6.8,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143938789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to the Korea National Committee on Immunization Programs' Letter","authors":"Joowon Lee","doi":"10.1002/jmv.70401","DOIUrl":"https://doi.org/10.1002/jmv.70401","url":null,"abstract":"","PeriodicalId":16354,"journal":{"name":"Journal of Medical Virology","volume":"97 5","pages":""},"PeriodicalIF":6.8,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143938786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"High Genetic Variability of Hepatitis B Virus in Blood Donors With Surface Antigen Positive But DNA Negative in Southern China","authors":"Xianlin Ye,&nbsp;Xiaoxian Xu,&nbsp;Yinnan Dang,&nbsp;Jinfeng Zeng,&nbsp;He Xie,&nbsp;Bin Li,&nbsp;Baoren He,&nbsp;Limin Chen","doi":"10.1002/jmv.70396","DOIUrl":"https://doi.org/10.1002/jmv.70396","url":null,"abstract":"<div>\u0000 \u0000 <p>In our previous studies, 45.2% of donations with HBV HBsAg reactive (+) by ELISA but negative (−) by NAT were confirmed to have HBV infections in Shenzhen Blood Center, China. However, the serological and molecular characteristics of this type of HBV infection remain unclear, and several donations with indeterminate results require further investigation. In this current study, blood donations with HBsAg ELISA+/DNA NAT− results were collected and further characterized by various serological tests, quantitative PCR (qPCR) and nested PCR from January, 2019 to December, 2021. Molecular characterizations of HBV DNAs were performed by DNA sequencing. Additionally, donations with indeterminate results were classified through a follow-up study to confirm whether they contain HBV DNA. Of 278 HBsAg ELISA+/DNA NAT− samples identified from the screening of 165 025 blood donations, 82 (82/278, 29.5%, including 52 males and 30 females) were confirmed HBsAg positive, leaving nine donations (9/278, 3.2%) with indeterminate results and 187 (187/278, 67.3%) as no HBV infections. Three serological patterns were observed among these 82 confirmed HBsAg positive donations: 74 samples were HBsAg+/anti-HBe+/anti-HBc+, seven samples were HBsAg+/anti-HBc+, and one sample was HBsAg+ alone. Sequence analysis showed that 45 (45/50, 90%) were genotype B, while 4 (4/50, 8%) were genotype C and 1 (1/50, 2%) was genotype D. Notable mutations such as Q101R, Q129H, M133L/T, F134L, L175S, V177A, and N-glycosylation mutations in S regions of HBV genotype B were observed. Additionally, high frequency mutations such as T1719G (33/35, 94.3%), A1752G/T (11/35, 31.4%), G1896A (26/35, 74.3%), and A1762T/G1764A (7/35, 20%) in the BCP/PC regions were also identified. All these mutations might contribute to low-level HBsAg and/or extremely low viral loads. Six out of nine donations (6/9, 66.7%) with indeterminate results were tested positive for both HBsAg and HBV DNA during 65–192 days of follow-up, and they were then confirmed as HBV infections. 31.7% donations with HBsAg ELISA+/NAT− results were confirmed as HBV infection. Various notable mutations identified in the BCP/PC and S regions may be responsible for the low viral loads and HBsAg level in these donations. Therefore, assays with high sensitivity, specificity, and ability to detect genetic variants (mutations) are essential for accurate blood screening in HBV-endemic countries/regions to prevent the transmission of HBV through blood transfusion.</p>\u0000 </div>","PeriodicalId":16354,"journal":{"name":"Journal of Medical Virology","volume":"97 5","pages":""},"PeriodicalIF":6.8,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143938788","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Viral Kinetics During Acute Chikungunya Virus Infection: Insights Into Potential Role of Monoclonal Antibodies in Viral Clearance and Prophylaxis Using Mathematical Modeling","authors":"Tey Putita Ou,&nbsp;Sopheak Sorn,&nbsp;Kunthy Nguon,&nbsp;Saraden In,&nbsp;Sreymom Ken,&nbsp;Sowath Ly,&nbsp;Claude Flamand,&nbsp;Nicolas Voirin,&nbsp;Marie Mandron,&nbsp;Hugh Watson,&nbsp;Veasna Duong","doi":"10.1002/jmv.70391","DOIUrl":"https://doi.org/10.1002/jmv.70391","url":null,"abstract":"<div>\u0000 \u0000 <p>Chikungunya virus (CHIKV), an arthritogenic alphavirus, is a significant public health threat in endemic and newly affected regions. This study investigates viral kinetics, immune responses, and the potential of monoclonal antibody (mAb) therapies to mitigate viraemia and transmission during acute CHIKV infection, providing novel insights into early intervention strategies. Using data from 29 patients in Cambodia, serial sampling and viral load quantification revealed that the population-average peak viral load occurred ~1.87 days prior to symptom onset. Children demonstrated higher peak viral loads and faster replication rates compared to adults, although symptom severity and burden were similar across age groups. IgM antibodies appeared earlier in adults (median: 4.1 days) than in children (median: 5.1 days; <i>p</i> = 0.036). C-reactive protein (CRP) levels were transiently elevated in about 50% of patients but showed no correlation with disease severity. Mathematical modeling highlighted that prophylactic mAb therapies, when administered 3 days before symptoms onset, could substantially reduce viral load and potentially prevent detectable viraemia. While these findings underscore the potential of mAbs as an early therapeutic strategy, further studies are necessary to evaluate the robustness of these results and assess their practical implications to curb CHIKV outbreaks by minimizing viraemia and presymptomatic transmission.</p></div>","PeriodicalId":16354,"journal":{"name":"Journal of Medical Virology","volume":"97 5","pages":""},"PeriodicalIF":6.8,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143938781","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"High Burden of Dengue and Chikungunya Virus in Paraguay: Seroprevalence Findings From Blood Donors","authors":"Diego M. Flichman,&nbsp;Nelson Marquez,&nbsp;Matías Javier Pereson,&nbsp;Victor A. Sánchez S,&nbsp;Andrea S. Gómez de la Fuente,&nbsp;Cecilia González,&nbsp;José Martín Lema,&nbsp;Sonia L. Espíndola,&nbsp;Graciela M. Carballo,&nbsp;Alfredo P. Martínez,&nbsp;Patricia Baré,&nbsp;Federico A. Di Lello","doi":"10.1002/jmv.70388","DOIUrl":"https://doi.org/10.1002/jmv.70388","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 <p>The rise of reemerging pathogens such as DENV and CHIKV presents a major public health threat. With half the global population at risk, Paraguay experiences particularly high infection rates. Despite this, data on the seroprevalence of these viruses in this country is lacking. This study aims to assess the seroprevalence of anti-DENV IgG and anti-CHIKV IgG among blood donors in Paraguay. Serum samples from 546 blood donors across seven regional districts and Asunción were collected from March to May 2023. Participants filled out a questionnaire and underwent eligibility screening. Serum samples were tested for anti-DENV IgG and anti-CHIKV IgG antibodies using immunoassays. Data were analyzed using IBM SPSS version 23.0. The median (IQR) age of donors was 34 (26–44), and 47.1% were female. Anti-DENV IgG prevalence was 87.7%, ranging from 73.7% to 100% by location, with an age-related association. Donors aged 18 to 25 had a 79.2% seroprevalence, while those over 46 had the highest at 91.5% (<i>p</i> = 0.010). Anti-CHIKV IgG prevalence was 37.2%, with men showing a seroprevalence nearly 10% higher than women, but no significant age-related differences were observed. Regional variation in CHIKV seroprevalence was not significant. In conclusion, this study suggests a high seroprevalence of both DENV and CHIKV in Paraguayan blood donors. The high DENV seroprevalence reflects the impact of past outbreaks, while the notable CHIKV prevalence underscores the effects of recent outbreaks. Continuous surveillance, improved diagnostics, and effective vector control measures are essential to mitigate these arboviruses' impact in Paraguay.</p>\u0000 </section>\u0000 </div>","PeriodicalId":16354,"journal":{"name":"Journal of Medical Virology","volume":"97 5","pages":""},"PeriodicalIF":6.8,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143938787","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative Analysis of Quan and Watanabe Pan-Coronavirus Assays for Bat Coronavirus Diversity in Sarawak, East Malaysia","authors":"Sultana Parvin Habeebur-Rahman,&nbsp;Faisal Ali Anwarali Khan,&nbsp;Jayasilan Mohd-Azlan,&nbsp;Melvin Gumal,&nbsp;Cheng Siang Tan,&nbsp;Sarawak Emerging Pathogen Surveillance Study Group","doi":"10.1002/jmv.70389","DOIUrl":"https://doi.org/10.1002/jmv.70389","url":null,"abstract":"<p>Bats are natural reservoirs for a diverse range of coronaviruses (CoVs), including those closely related to SARS-CoV and SARS-CoV-2, making them crucial for understanding CoV genetics and zoonotic transmission. The exceptional bat diversity in Sarawak, Malaysian Borneo, provides an ideal setting to investigate CoV diversity and potential transmission pathways. This study examined CoV prevalence and diversity in 346 fecal samples from bats across 29 species in northern and western Sarawak, employing two pan-CoV PCR assays: Quan (Q-assay) and Watanabe (W-assay). The Q-assay and W-assay estimated the CoV prevalence to be 14.45% and 12.72%, respectively. The overall true prevalence based on both assays was 22.83%. There was a fair agreement between both assays (<i>κ</i> = 0.286) with comparable performance in detecting the virus (McNemar <i>p</i> &gt; 0.05). Phylogenetic analyses identified six distinct clades within alphacoronaviruses (α-CoVs) and betacoronaviruses (β-CoVs), comprising two unclassified Borneo-Alpha CoVs and four from the subgenera <i>Minunacovirus</i>, <i>Rhinacovirus</i>, <i>Nobecovirus</i>, and <i>Sarbecovirus</i>. This study represents the first report of Sarawak bat CoVs derived from rectal and fecal samples, addressing a significant knowledge gap. The findings highlight the need for complementary molecular assays to enhance CoV surveillance and deepen understanding of viral ecology in regions of high biodiversity, with implications for zoonotic disease prevention.</p>","PeriodicalId":16354,"journal":{"name":"Journal of Medical Virology","volume":"97 5","pages":""},"PeriodicalIF":6.8,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jmv.70389","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143938782","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identifying Neurological Autoantibodies in COVID-19: mGluR2 as a Marker of Immune Dysregulation During the Omicron Outbreak in China","authors":"Ziyan Wu,&nbsp;Siyuan Fan,&nbsp;Honglin Xu,&nbsp;Futai Feng,&nbsp;Zhan Li,&nbsp;Linlin Cheng,&nbsp;Haolong Li,&nbsp;Yongmei Liu,&nbsp;Haoting Zhan,&nbsp;Xinxin Feng,&nbsp;Siyu Wang,&nbsp;Shulan Zhang,&nbsp;Yongzhe Li","doi":"10.1002/jmv.70381","DOIUrl":"https://doi.org/10.1002/jmv.70381","url":null,"abstract":"<div>\u0000 \u0000 <p>Aimed to comprehensively investigate the presence of neural autoantibodies in the cerebrospinal fluid (CSF) and plasma of COVID-19 patients experiencing neurological complications during the Omicron wave in China. Forty consecutive COVID-19 patients with severe neurological complications and 15 disease controls (DC) were enrolled. Neural autoantibodies were detected using both the indirect immunofluorescence assay (IFA) on mouse brain tissue and the Brain-neuronal-antigen microarray. Our results indicated a significantly higher prevalence of neural autoantibodies in the CSF (62.16% vs. 0.0%) and plasma (38.71% vs. 13.33%) of COVID-19 patients compared to DC. Additionally, we identified 12 upregulated intrathecal IgG autoantibodies with differential levels between COVID-19 patients and DC, as well as 51 upregulated IgG autoantibodies in plasma. A high prevalence of anti-mGluR2 antibodies (13.33%) in COVID-19 patients was confirmed by cell-based assays. Western blot analysis showed these antibodies cross-react with both the nucleocapsid (N) and spike (S) proteins of SARS-CoV-2. Notably, strong binding to both the S protein's RBD-Fc and mGluR2 was observed, an association that was substantiated by bioinformatics analysis evaluating the similarity between SARS-CoV-2 proteins and the targeted antigens on the microarray. This finding hints at a potential cross-reactivity between anti-mGluR2 antibodies and the S protein in COVID-19 patients.</p></div>","PeriodicalId":16354,"journal":{"name":"Journal of Medical Virology","volume":"97 5","pages":""},"PeriodicalIF":6.8,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143919345","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epidemiology and Clinical Features of Epstein-Barr Virus and Cytomegalovirus Infections in Japanese Infants and Young Children","authors":"Yotaro Kondo,&nbsp;Yuki Higashimoto,&nbsp;Fumihiko Hattori,&nbsp;Yoshiki Kawamura,&nbsp;Kei Kozawa,&nbsp;Hiroki Miura,&nbsp;Akiko Yoshikawa,&nbsp;Masaru Ihira,&nbsp;Jun-Ichi Kawada,&nbsp;Tetsushi Yoshikawa","doi":"10.1002/jmv.70383","DOIUrl":"https://doi.org/10.1002/jmv.70383","url":null,"abstract":"<div>\u0000 \u0000 <p>The recent clinical features of Epstein-Barr virus (EBV) and cytomegalovirus (CMV) infections in young children in developed countries remain unclear. This study investigated the clinical features of EBV and CMV infections and the latest seroepidemiology in Japan. Seroprevalence was analyzed 303 stored serum samples using commercial Enzyme Immunosorbent Assay kits, and viral infections were investigated in a cohort of febrile children under 5 years of age. After maternal antibody levels declined, the seroprevalences of EBV and CMV gradually increased by adolescence to 42.9% and 57.1%, respectively. Among 2,732 febrile children, serum EBV and CMV DNAs were detected in 1.76% and 1.24%, respectively. Of 25 primary EBV–infected patients, 15 (60.0%) had infectious mononucleosis (IM) with significantly higher IM frequency, WBC, atypical lymphocyte ratios, AST, ALT, LDH, and EBV DNA load compared to EBV–reactivated patients. No CMV DNA–positive patients had IM. Among primary EBV–infected patients, those with IM were older and had more atypical lymphocytes and higher EBV DNA load than those without IM. The age of primary EBV infection appears to have decreased compared to reports from Western countries in the 1990s. Even among children under 5 years of age, 60.0% of those with primary EBV infection developed IM.</p>\u0000 </div>","PeriodicalId":16354,"journal":{"name":"Journal of Medical Virology","volume":"97 5","pages":""},"PeriodicalIF":6.8,"publicationDate":"2025-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143914568","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative Analysis of Early COVID-19 Treatment Efficacy in a Multicentric Regional Cohort in Italy: Emulation of a Series of Target Trials","authors":"Valentina Mazzotta,&nbsp;Alessandro Cozzi Lepri,&nbsp;Cosmo Del Borgo,&nbsp;Simone Lanini,&nbsp;Silvia Meschi,&nbsp;Silvia Garattini,&nbsp;Silvia Rosati,&nbsp;Valentina Siciliano,&nbsp;Alessandra Vergori,&nbsp;Luigi Coppola,&nbsp;Antonio Falletta,&nbsp;Anna Carraro,&nbsp;Giulia Gramigna,&nbsp;Alessandra Oliva,&nbsp;Elena Matteini,&nbsp;Andrea Gasperin,&nbsp;Giuseppina Giannico,&nbsp;Ilaria Mastrorosa,&nbsp;Giulia Matusali,&nbsp;Alessandra D'Abramo,&nbsp;Raffaella Marocco,&nbsp;Eugenia Milozzi,&nbsp;Carlotta Cerva,&nbsp;Francesca Gavaruzzi,&nbsp;Martina Rueca,&nbsp;Claudia Cimaglia,&nbsp;Pierluca Piselli,&nbsp;Massimo Fantoni,&nbsp;Enrico Girardi,&nbsp;Loredana Sarmati,&nbsp;Claudio M. Mastroianni,&nbsp;Massimo Andreoni,&nbsp;Carlo Torti,&nbsp;Emanuele Nicastri,&nbsp;Fabrizio Maggi,&nbsp;Miriam Lichtner,&nbsp;Andrea Antinori,&nbsp;The Early Treatment for COVID-19 Lazio Study Group","doi":"10.1002/jmv.70379","DOIUrl":"https://doi.org/10.1002/jmv.70379","url":null,"abstract":"<p>Studies comparing all available strategies for the early treatment of mild-to-moderate COVID-19 during the Omicron era are lacking. We included people with mild-to-moderate COVID-19 and at high risk of progressing to severe disease attending five outpatient clinics in Italy over 2022–2023. The primary outcome was the proportion of participants who experienced Day-30 hospitalization due to COVID-19 or death. Participants received either nirmatrelvir/ritonavir (NMV/r), molnupiravir (MLP), remdesivir (RDV), sotrovimab (SOT), or tixagevimab/cilgavimab (TIX/CIL). We included 10 038 individuals: females 5052 (50%), median age 71 years (IQR 59–81). In total, 1919 (19%) received SOT, 3732 (37.2%) MLP, 1444 (14%) RDV, 2510 (25%) NMV/r, and 433 (4%) TIX/CIL. Only 1689 (17%) had incomplete vaccination, and 2435 (24.3%) were not immunocompetent. The rate of hospitalization/death was 2.40% (95% CI 2.10–2.71). Unadjusted rates were 0.88% (95% CI 0.55–1.32) for NMV/r, 1.69% (95% CI 1.30–2.15) for MLP, 3.0% (95% CI 1.61–5.08) for TIX/CIL, 3.54% (95% CI 2.76–4.47) for SOT and 5.12% (95% CI 4.05–6.39) for RDV. Weighted analysis showed that NMV/r and MLP were superior to all other interventions. In our population of individuals at high risk of progression to severe disease, there was clinical benefit in using NMV/r or MLP instead of mAbs-based therapies or RDV.</p>","PeriodicalId":16354,"journal":{"name":"Journal of Medical Virology","volume":"97 5","pages":""},"PeriodicalIF":6.8,"publicationDate":"2025-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jmv.70379","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143909352","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dynamics of SARS-CoV-2 Spike Receptor-Binding Domain-Targeted Specific Peripheral Memory B Cells in Patients With End-Stage Chronic Kidney Disease Undergoing Replacement Therapy Following COVID-19 Vaccination","authors":"Ángela Sánchez-Simarro,&nbsp;Nayara Panizo,&nbsp;Estela Giménez,&nbsp;Eliseo Albert,&nbsp;Marco Montomoli,&nbsp;Irina Sanchis,&nbsp;Julia Kanter,&nbsp;José Luis Górriz,&nbsp;David Navarro","doi":"10.1002/jmv.70382","DOIUrl":"https://doi.org/10.1002/jmv.70382","url":null,"abstract":"<div>\u0000 \u0000 <p>Memory B cells (MBCs) are responsible for maintaining long-lasting functional B-cell immune responses. Little is known about the kinetics of peripheral blood (PB) SARS-CoV-2 vaccine-induced MBCs in end-stage chronic kidney disease (CKD) patients undergoing replacement therapies. We investigated this issue in this prospective, observational cohort study including 27 patients (9 females and 18 males; median age, 68.4 years, range 48–82) comprising 20 hemodialysis patients and 7 Kidney transplant recipients. SARS-CoV-2-Receptor-Binding Domain (RBD)-targeted PB-MBCs were enumerated by flow cytometry using a tetramer-binding assay after the second COVID-19 mRNA vaccine dose (Post-2D), before (Pre-3D), and after the first mRNA vaccine booster dose (Post-3D). Commercially available electrochemiluminescent immunoassays were used to measure total anti-RBD antibodies targeting an IgG against the S trimeric protein. Overall, 18/27 patients (66.6%) exhibited detectable RBD-MBC responses at Post-2D, 12/27 (44.4%) at Pre-3D, and 16/27 (59.2%) at Post-3D. RBD-MBC levels dropped non-significantly between post-2D and Pre-3D (<i>p</i> = 0.38). A nonsignificant increase in RBD-MBCs was noticed post-3D (<i>p</i> = 0.65). Overall, both antibody specificities displayed the same dynamics but the drop in anti-trimeric spike antibody levels between Post-2D and Pre-3D and increases post-3D were statistically significant (<i>p</i> &lt; 0.001). No correlation (rho = 0.05; <i>p</i> = 0.64) was observed between total antibodies against RBD and RBD-MBC counts. The correlation between IgG antibodies against the trimeric S protein and SARS-CoV-2 RBD-MBC counts was very weak (rho, 0.18; <i>p</i> = 0.11). In summary, waning RBD-MBC counts Pre-3D and increases post-3D are less marked than that of anti-RBD and anti-S trimeric antibodies.</p>\u0000 </div>","PeriodicalId":16354,"journal":{"name":"Journal of Medical Virology","volume":"97 5","pages":""},"PeriodicalIF":6.8,"publicationDate":"2025-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143909348","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}